和誉-B(02256)发布公告，于2025年8月20日该公司斥资160.73万港元回购10万股，回购价格为每股15.71- 16.36港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年8月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02256 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | ...

| 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | (請參閱上述*註 有投票權股期(日/月/ 份權益 | | | | | | | | 份百分比 年) | | | | | | | | ( %) | | | CS20250818E00345 | Allianz SE 1001(L) 1.957.000(L) | | | HKD 15.6938 | 34.652.000(L) | 5.10(L) 15/08/2025 | 增持后，Allianz SE最新持股数目为3465.2万股，持股比例由4.81%上升至5.10%。 | 股份代號: | 02256 | | --- | --- | | 上市法國名稱: | 和譽開曼有限責任公司 - B | | 日期 (日 / 月 / 年): | 20/07/2025 - 20/08/2025 | 格隆汇8月20日丨根据联交所最新权益披露 ...

Core Viewpoint - The stock of He Yu-B (02256) has seen significant gains, rising over 60% in the month, driven by its inclusion in the MSCI Global Small Cap Index and strong financial performance [1] Group 1: Stock Performance - He Yu-B's stock price reached a new high of 17.5 HKD, with a current increase of 6.37% to 17.03 HKD [1] - The stock has experienced a cumulative increase of over 60% within the month [1] Group 2: MSCI Inclusion - On August 13, He Yu-B announced its inclusion in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - This inclusion is expected to lead to increased buying from passive funds, such as ETFs, enhancing market liquidity and international visibility for the company [1] Group 3: Financial Performance - For the first half of the year, He Yu-B reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a year-on-year increase of 59% [1] - The strong performance was attributed to higher-than-expected income from Merck's exercise [1] Group 4: Analyst Insights - CICC noted that the company's performance exceeded expectations, while Citigroup highlighted that the current valuation is low [1] - Citigroup emphasized the high certainty of the late-stage candidates pimicotinib and irpagratinib, suggesting potential for external licensing [1] - The firm anticipates a high success rate for the Phase III clinical trial of irpagratinib for second-line liver cancer, which should be factored into the company's valuation [1]

Core Viewpoint - The stock of He Yu-B (02256) has seen significant gains, rising over 60% in the month, driven by its inclusion in the MSCI Global Small Cap Index and strong financial performance [1] Group 1: Stock Performance - He Yu-B's stock price reached a new high of 17.5 HKD, with a current increase of 6.37% to 17.03 HKD [1] - The stock has experienced a cumulative increase of over 60% within the month [1] Group 2: MSCI Inclusion - On August 13, He Yu-B announced its inclusion in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - This inclusion is expected to lead to increased buying from passive funds, such as ETFs, enhancing market liquidity and international visibility for the company [1] Group 3: Financial Performance - For the first half of the year, He Yu-B reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a year-on-year increase of 59% [1] - The strong performance was attributed to better-than-expected income from Merck's exercise [1] Group 4: Analyst Insights - CICC noted that the company's performance exceeded expectations, while Citigroup highlighted that the current valuation is low [1] - Citigroup emphasized the high certainty of the late-stage candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipelines to secure external licensing [1] - The success rate of the Phase III clinical trial for irpagratinib in second-line liver cancer is expected to be very high, which should be factored into the company's valuation [1]

Group 1: Market Overview - The Hang Seng Index rose by 1.88%, gaining 470 points to close at 25,439 points, while the Hang Seng Tech Index increased by 2.35% [1] - The early trading volume in the Hong Kong stock market reached HKD 143.8 billion [1] Group 2: Biotechnology Sector - The Hang Seng Biotechnology Index surged by 3.77%, driven by a collective rise in pharmaceutical stocks following the debut of the "dual directory" for drug applications [1] - Zhonghui Biotech-B (02627) saw a significant increase of 24%, while Jiuyuan Gene (02566) rose by 8.99%, and Kintor Pharmaceutical (09939) increased by 5.7% [1] - Innovent Biologics (01801) experienced a rise of 7.27%, and He Yu-B (02256) reached a new high with a 7.38% increase, reporting a 59% year-on-year growth in net profit for the first half of the year [1] Group 3: Pharmaceutical Developments - Daqi Pharmaceutical-B (06996) rose over 15% as Claudin 18.2 ADC was proposed for inclusion as a breakthrough therapy [2] Group 4: Technology Sector - Tencent's subsidiaries reported generally better-than-expected earnings, with Tencent Music-SW (01698) rising by 15%, and Reading Group (00772) also increasing by over 15% [2] - Weimeng Group (02013) saw an increase of over 7% [2] Group 5: Industrial and Manufacturing Sector - Chongqing Machinery (02722) rose by 8.9%, with an expected 50% year-on-year growth in net profit due to rapid growth in AIDC engine demand [3] - Zhongyan Hong Kong (06055) increased by over 7%, maintaining its position in the domestic cigarette export tax-free business, with earnings to be announced next Friday [3] Group 6: Technology and Electronics - Qiu Tai Technology (01478) rose by over 8%, reporting a 167% year-on-year increase in net profit for the first half of the year, leading to target price upgrades from multiple institutions [4] - Hong Teng Precision (06088) increased by over 9% post-earnings, with a cumulative rise of over 60% in the month, reporting an 11% revenue growth but a 3% decline in net profit [5] - Minmetals Resources (01208) rose by over 9% after reporting a 15-fold increase in net profit for the first half of the year and lowering cost guidance for its mines [6] Group 7: Performance Review - 361 Degrees (01361) fell by over 10% post-earnings, with institutions stating that the first half performance met expectations, but net profit growth was slightly lower than revenue growth [7]

Core Viewpoint - HeYue-B (02256) has seen a significant stock price increase of nearly 40% post-earnings, reaching a historical high of 14.65 HKD, driven by strong financial performance and positive market sentiment [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The profit for the same period was 328 million HKD, showing a substantial year-on-year increase of 59% [1] Key Drivers - The earnings exceeded expectations primarily due to Merck's exercise of the commercialization option for pimicotinib, which resulted in a one-time fee of 85 million USD received in May [1] - The company announced that Merck exercised its global commercialization option for pimicotinib in April [1] Market Outlook - Citigroup has indicated that the current valuation of HeYue is low, considering the high certainty of its two late-stage candidates, pimicotinib and irpagratinib, along with a differentiated innovation pipeline that may lead to external licensing opportunities [1] - The firm anticipates significant catalysts for the company in 2025 and 2026, focusing on the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061 [1]

和誉-B(02256)再涨近9%，绩后累计涨幅接近四成，盘中高见14.65港元再创历史新高。截至发稿，涨 8.27%，报14.53港元，成交额7697.68万港元。 消息面上，8月5日，和誉医药发布业绩，今年上半年，公司实现营收6.12亿元，同比增长23%；利润 3.28亿元，同比增长59%。中金表示，公司业绩超预期，主要由于默克行权收入超预期。据悉，今年4 月，和誉医药宣布默克行使匹米替尼的全球商业化选择权；5月，和誉医药收到了默克的全球商业化选 择权行权费8500万美元。 花旗表示，和誉当前估值偏低，基于其2款晚期候选药pimicotinib(匹米替尼)与irpagratinib(依帕戈替尼) 都具高度确定性，且差异化创新管线有望实现对外授权。该行预期依帕戈替尼二线肝细胞癌三期临床试 验的成功率极高，其估值应被纳入考量因素。花旗认为，和誉在2025及2026年将会有关键催化剂出现， 关注其匹米替尼上市审批及商业化表现、依帕戈替尼三期数据公布，以及ABSK043及ABSK061等多项 候选药物的数据更新，和潜在的商业合作。 ...

Core Viewpoint - HeYue-B (02256) has seen a significant stock price increase of nearly 9% post-earnings, with a cumulative rise of close to 40%, reaching a historical high of 14.65 HKD, driven by strong financial performance and positive market sentiment [1] Financial Performance - For the first half of the year, HeYue reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a substantial year-on-year increase of 59% [1] Market Reactions - CICC noted that the company's performance exceeded expectations, primarily due to higher-than-expected income from Merck [1] - Citigroup highlighted that HeYue's current valuation is low, considering the high certainty of its two late-stage candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipeline to secure external licensing [1] Future Catalysts - Citigroup anticipates key catalysts for HeYue in 2025 and 2026, focusing on the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061, along with potential commercial collaborations [1]

Core Viewpoint - The stock price of HeYu-B (02256) has surged nearly 200% year-to-date, driven by favorable policies and a warming investment climate in the Hong Kong innovative drug sector, leading to increased emphasis on the commercialization capabilities of innovative drug companies [1][2]. Group 1: Stock Performance and Market Recognition - On August 11, the company's stock price surpassed the IPO price of HKD 12.46, closing up 5.93%, and reached a new high of HKD 13.67 the following day [1]. - HeYu was included in the MSCI Global Small Cap Index, which tracks over USD 17 trillion in assets, enhancing its market liquidity and international visibility [4]. Group 2: Innovation and Financial Performance - HeYu's core product, Pimicotinib, is the first Chinese-developed CSF-1R inhibitor entering global Phase III clinical trials, with significant potential in various indications [5][6]. - The company secured a high-value partnership with Merck, receiving an upfront payment of USD 70 million, which is expected to lead to its first annual profit in 2024 [5][7]. - HeYu has maintained around HKD 2 billion in cash reserves over the past three years, ensuring financial stability and supporting ongoing R&D efforts [9]. Group 3: Pipeline and Future Prospects - HeYu's pipeline includes multiple innovative drugs, with Pimicotinib and the FGFR4 inhibitor Irpagratinib being highlighted as potential blockbuster products [10]. - The company has presented promising preclinical results at major conferences, showcasing its advancements in small molecule innovation [10]. - HeYu's stock buyback program, amounting to HKD 200 million, reflects its commitment to returning value to shareholders while maintaining a low price-to-sales (PS) ratio of 13.38, indicating significant growth potential [11].